# Core Fusion Peptides — Recovery & Tissue Repair Research Peptides > Core Fusion Peptides is a reference desk for multi-peptide repair blends studied for recovery and tissue repair — Wolverine, KLOW, and GLOW — summarized from peer-reviewed literature. A digest, not a vendor or clinic. A calm reading desk for the published science on Wolverine (BPC-157 + TB-500), KLOW, and GLOW — what each blend's constituents were actually studied for, in which species, and how strong the evidence really is. ## The short version Core Fusion Peptides is a reading desk, not a store. It collects what the published research literature says about three multi-peptide blends that keep appearing in conversations about **recovery and tissue repair**: Wolverine (BPC-157 + TB-500), KLOW, and GLOW. A *peptide* is just a short chain of amino acids — the same building blocks as proteins, only far smaller. Each blend combines two to four peptides because their individual mechanisms are thought to address different steps in the repair process: growing new blood vessels, helping cells migrate into a wound, building the collagen scaffolding that holds tissue together, calming inflammation, or remodeling the skin matrix. This desk does one job: it tells you, in plain language and with citations, what each blend's constituents were tested on, in which species, and how far that evidence reaches. Most of it stops well short of humans. None of these blends is approved as a medicine, and there are no controlled studies of any of the blends themselves. We do not sell anything, we do not give medical advice, and we never list a human dose. ## What are research peptides? Proteins — collagen in a tendon, an enzyme in your gut, a signaling hormone — are long chains of amino acids folded into a shape. A *peptide* is a much shorter chain of the same building blocks, sometimes only three or four links long. Because they are small and specific, peptides can act like keys that fit particular locks (receptors) on the surface of cells, switching certain biological processes on or off. A *research peptide* is one that has been synthesized and studied in the laboratory — in cell cultures, in animals, occasionally in early human pilots — but has **not** been approved by a regulator as a medicine. Sellers describe these compounds as being for laboratory research only, and that framing matters: it means dosing, long-term safety, and effectiveness in people are usually unestablished. When this desk reports a number, it reports it the way the study did — for example, *studied at 10 micrograms per kilogram in rats* — never as a recommendation. ## How these three blends fit into repair research The three blends on this desk are built from overlapping component peptides, which is exactly what makes reading them together useful. - [**Wolverine**](/wolverine) is the lead. It pairs BPC-157 — a fifteen-amino-acid gastric pentadecapeptide studied for angiogenesis and cytoprotection — with TB-500, the synthetic actin-binding fragment of thymosin beta-4. The two-mechanism rationale is that BPC-157 drives new blood-vessel growth into damaged tissue [4] while TB-500 / thymosin beta-4 governs the cytoskeletal dynamics that let repair cells migrate [5][6]. No controlled study of the Wolverine combination exists [2]. - [**KLOW**](/klow) extends Wolverine's two-peptide core by adding GHK-Cu (a copper-carrying tripeptide that remodels the collagen matrix and modulates gene expression across repair pathways [9][10]) and KPV (the anti-inflammatory tripeptide tail of alpha-MSH that suppresses NF-kB and MAPK signaling and reaches inflamed tissue via a dedicated transporter [11]). Together these four occupy the cytokine, matrix, vascular, and cytoskeletal nodes of one repair network — though the four-peptide combination has never been tested in any controlled study. - [**GLOW**](/glow) takes Wolverine's BPC-157 and TB-500 core and pairs them with GHK-Cu in place of KPV, positioning the blend at the intersection of connective-tissue recovery and skin renewal. The combination thesis is that GHK-Cu's collagen-stimulating, matrix-remodeling signal [10][12] works alongside BPC-157's angiogenic signal [4] and the cell-migration arm contributed by the thymosin beta-4 fragment [5]. See each compound page for the full research picture, or [compare these blends](/compare) side by side. ## A note on how this desk reads the literature Core Fusion Peptides is a cross-referenced literature digest. Each blend page summarizes the peer-reviewed studies for that combination's constituent peptides, cites them by number, and links to a single shared [references list](/references) that aggregates every source. Where evidence is thin, single-lab, preclinical, or rests on a parent molecule rather than the marketed compound, we say so plainly — that candor about limits is the point of the desk, not a footnote. A critical structural point runs through every page: not one of these three blends has been tested in a controlled study against its parts or against placebo. All combination claims are extrapolations from single-component research, and we say so each time they appear. --- A literature digest of research-peptide blend constituents — citations and cautions, never a dose and never a product.